Founder bio
Rugia BioIntel was founded by Klesti Karaxhuku, a PhD researcher at Imperial College London specialising in cell immunotherapy, with direct bench experience in next-generation cell therapy platforms targeting haematological malignancies.
Most biotech intelligence is produced by generalist analysts working from press releases and public filings. Rugia is built by someone who runs the experiments giving our clients a level of biological depth that changes how they evaluate opportunities.
The Story
Rugia BioIntel is a specialist biotech intelligence platform providing deep scientific and competitive analysis across immunotherapy and haematology therapeutics.
We translate complex biology into clear, actionable intelligence, helping biotech investors, venture capital firms, and life sciences companies evaluate opportunities, identify pipeline risks, and make high-conviction strategic decisions.
Our edge is simple: our analysis is written by scientists who run the experiments, not generalist analysts who read about them.